Related Experiment Videos
Single doses of FK506 and OKT3 reduce severity in early experimental acute pancreatitis
Objective:
To find out if two immunomodulatory drugs used in organ transplantation (FK506 (tacrolimus) and OKT3 (Orthoclone) would reduce early inflammatory complications in experimental acute pancreatitis.
Design:
Laboratory study.
Setting:
University hospital, Germany.
Animals:
36 Balb/c mice.
Interventions:
Pancreatitis induced by 7 intraperitoneal injections of cerulein 50 microg/kg at hourly intervals followed by FK506 0.32 mg/kg, OKT3 0.6 mg/kg, or 0.9% sodium chloride (controls) (n = 12 in each group). 12 hours after induction of pancreatitis the animals were killed.
Main Outcome Measures:
Serum amylase activity and interleukin-6 (IL-6) concentrations; histological damage to pancreas and lungs, apoptotic cells in pancreas; and myeloperoxidase activity in lungs.
Results:
No animal died during the experiment. At 12h serum amylase activity and IL-6 concentrations were increased in all 3 groups, but highest in the OKT3 group. The pancreatic histological score, apoptosis, and inflammatory infiltration were lower in the two experimental groups than controls, but the degree of vacuolisation of acinar cells was similar. Packed cell volume was higher in the control than the experimental groups, and pulmonary damage and myeloperoxidase activity were less in the experimental groups than the controls.
Conclusion:
Single therapeutic doses of FK506 and OKT3 reduced the early severity of pancreatitis, pulmonary damage, and haemoconcentration in mice. Single doses of FK506 or OKT3 may therefore be effective in preventing the early complications of pancreatitis.
Insights
Two immunomodulatory drugs, FK506 (tacrolimus) and OKT3 (Orthoclone), significantly reduced early inflammatory complications and organ damage in experimental acute pancreatitis in mice.
Area of Science:
- Immunology
- Gastroenterology
- Transplantation Medicine
Background:
- Acute pancreatitis is a severe inflammatory condition with significant morbidity and mortality.
- Early inflammatory complications, including multi-organ dysfunction, are a major challenge in managing acute pancreatitis.
- Immunomodulatory drugs like FK506 and OKT3 are used in organ transplantation but their role in pancreatitis is less understood.
Purpose of the Study:
- To investigate the efficacy of FK506 (tacrolimus) and OKT3 (Orthoclone) in mitigating early inflammatory complications of experimental acute pancreatitis.
- To assess the impact of these immunomodulatory agents on pancreatic and pulmonary damage, and systemic inflammatory markers.
Main Methods:
- A laboratory study involving 36 Balb/c mice.
- Acute pancreatitis was induced using cerulein injections.
- Mice received either FK506, OKT3, or saline (control) intraperitoneally.
- Evaluated serum amylase, IL-6, histological damage, apoptosis, and myeloperoxidase activity.
Main Results:
- Both FK506 and OKT3 treatments reduced pancreatic histological scores, apoptosis, and inflammatory infiltration compared to controls.
- Pulmonary damage and myeloperoxidase activity were significantly lower in the FK506 and OKT3 groups.
- Hemoconcentration, indicated by packed cell volume, was reduced by the immunomodulatory drugs.
Conclusions:
- Single therapeutic doses of FK506 and OKT3 effectively reduced the early severity of experimental acute pancreatitis in mice.
- These drugs also mitigated associated pulmonary damage and hemoconcentration.
- FK506 and OKT3 show potential as therapeutic agents for preventing early complications of acute pancreatitis.